A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

NCT06571266 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Risankizumab

Sponsor

AbbVie